A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy
Study of DSP-7888 in Combination with Bevacizumab in Patients with Recurrent or Progressive Glioblastoma
Sponsor: Sumitomo Dainippon Pharma Oncology, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR4631
U.S. Govt. ID: NCT03149003
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see if the newly discovered vaccine drug, DSP-7888, will help your immune system to fight against cancer cells that have a protein called WT1. The study will also compare the effectiveness of treatment with DSP-7888 in combination with Bevacizumab versus Bevacizumab alone in patients with glioblastoma (GBM). Bevacizumab has been approved by the FDA to treat GBM.
This study is closed
Mary Welch, MD
Do You Qualify?
Have you been diagnosed with glioblastoma? Yes No
Have you had prior therapy with Bevacizumab? Yes No
Are you able to live at home and care for most of your personal needs? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator